Cisplatin remains one of the most effective chemotherapeutic agents for treating solid tumors, yet its clinical application is frequently hindered by nephrotoxicity. This adverse effect arises primarily from the drug’s accumulation in renal proximal tubular cells, leading to oxidative stress, mitochondrial dysfunction, inflammation, and apoptosis. Despite the use of aggressive hydration protocols—considered the gold standard—nephrotoxicity still occurs in approximately 10% to 30% of patients. Therefore, there is a critical need for safe and effective adjunctive therapies that can further reduce renal damage without compromising antitumor efficacy.
Selenium, a trace element essential for selenoprotein synthesis, plays a pivotal role in cellular antioxidant defense systems. It functions as a cofactor for glutathione peroxidase and thioredoxin reductase, enzymes that neutralize hydrogen peroxide and lipid hydroperoxides, thereby preventing oxidative damage to lipids, proteins, and DNA. By preserving redox homeostasis, selenium may protect renal tubular cells from cisplatin-induced injury. Preclinical studies have demonstrated reduced kidney histopathology and improved survival in selenium-treated animals exposed to cisplatin. However, clinical evidence remains limited and inconsistent.
This prospective, double-blind, randomized controlled trial evaluated the efficacy and safety of oral selenium supplementation in 122 adult cancer patients receiving cisplatin-based chemotherapy. Patients were randomly assigned using sealed opaque envelopes to receive either a single 400 mcg selenium tablet or a placebo the day before chemotherapy initiation. All participants received standard intravenous hydration with 3 liters of normal saline and 40 mg furosemide on day one. Primary endpoints included development of acute kidney injury (AKI) defined by an increase in serum creatinine above 1.5 mg/dL in men or 1.4 mg/dL in women, a rise exceeding 50% from baseline, or urine output less than 0.5 mL/kg/h. Secondary outcomes included changes in urinary biomarkers of tubular injury (NAG, α1-microglobulin, NGAL), serum oxidative stress markers (MDA, TOS), and antioxidant capacity (TAC).
Baseline characteristics—including age, sex, type of malignancy, prior chemotherapy exposure, comorbidities, and cumulative cisplatin dose—were well balanced between groups (p > 0.05). No significant differences were observed in the mean cumulative cisplatin dose (203.72 mg in both groups; p = 0.54). Notably, seven patients in the placebo group developed AKI, whereas no cases occurred in the selenium group (p = 0.013). Urinary NAG levels increased significantly in the placebo group but remained stable in the selenium cohort (p < 0.01). Similarly, α1-microglobulin and NGAL were markedly elevated in the control arm, indicating tubular epithelial damage, while selenium recipients showed minimal changes.Ataluren Biological Activity
Biochemical analysis revealed a significant reduction in malondialdehyde (MDA) and total oxidant status (TOS) in the selenium group (p < 0.001), accompanied by a substantial increase in total antioxidant capacity (TAC) (p < 0.001). These findings confirm that selenium effectively attenuates systemic oxidative stress induced by cisplatin.Vedolizumab Description Importantly, no serious adverse events related to selenium supplementation were reported, and there was no difference in overall treatment tolerance or chemotherapy completion rates between groups.PMID:35089878
These results strongly suggest that selenium supplementation provides significant protection against cisplatin-induced acute kidney injury when administered alongside standard hydration. The mechanism likely involves enhancement of endogenous antioxidant defenses, reducing oxidative damage to renal tubules. Given its low cost, favorable safety profile, and ease of administration, selenium represents a viable and practical strategy for improving renal safety in oncology patients. Future multicenter trials with longer follow-up and repeated dosing regimens are warranted to confirm these findings and establish optimal dosing schedules.MedChemExpress (MCE) offers a wide range of high-quality research chemicals and biochemicals (novel life-science reagents, reference compounds and natural compounds) for scientific use. We have professionally experienced and friendly staff to meet your needs. We are a competent and trustworthy partner for your research and scientific projects.Related websites: https://www.medchemexpress.com